Source: International Congress 2018 – Fungal infection in the intensive care unit



Rating:

Share or cite this content

Citations should be made in the following way:
A. Cortegiani (Palermo, Italy). The evidence regarding early antifungal treatment. International Congress 2018 – Fungal infection in the intensive care unit

Member's Comments

No comment yet.

Related content which might interest you: The frequency of prescribing antimicrobial drugs in the initial therapy of COVID-19 at the outpatient stage Source: Virtual Congress 2021 – COVID - 19 treatments Year: 2021 Antiviral therapy – the evidence base and clinical trials Source: International Congress 2015 – PG11 Emerging infectious diseases and pandemic planning Year: 2015 Anti-IgE therapy: rationale and clinical evidence Source: Annual Congress 2007 - Changing practice with anti-IgE: patient, physician and payor perspectives Year: 2007 The clinical and bacteriological basis for initiating a specific treatment Source: Annual Congress 2006 - PG11 - Clinical highlights on tuberculosis Year: 2006 Biological resistance to beta-lactamic antibiotics in patients with respiratory infection in the prediction of efficiency of antibacterial therapy Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 The possibility of strengthening of activity of antituberculous drugs: preliminary results Source: Annual Congress 2004 - Management of tuberculosis Year: 2004 New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 First evidence for a gut-lung axis influencing murine lung immunity upon early life antibiotic treatment Source: International Congress 2018 – Identification of therapeutic targets for asthma Year: 2018 Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001 The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 Sputum induction for assessment of biomarkers in early development of new drugs for respiratory disease in a proof of concept setting Source: International Congress 2016 – Airway biomarkers Year: 2016 The search for evidence of the efficacy of augmentation therapy in AATD Source: Annual Congress 2013 –Alpha-1 antitrypsin deficiency and the lung: celebrating the 50th anniversary of its first description Year: 2013 The effect of addition of macrolide to a beta-lactam antibiotic on treatment success in patients with moderately severe community acquired pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 The adverse effects of multidrug resistant tuberculosis treatment and relationship with treatment results Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Paradox radiologic progression despite appropriate antituberculosis therapy Source: Annual Congress 2011 - Management of tuberculosis Year: 2011 An analysis of non-effective empiric antibacterial therapy in COPD acute exacerbation Source: Annual Congress 2007 - Miscellaneous lower respiratory tract infections Year: 2007